InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total revenue | $20.3M+1945.6% | $992K+112.9% | $466K |
| Cost of product revenue | $2.2M+18.3% | $1.9M+541.2% | $289K |
| Cost of license and collaboration revenue | $1.2M+40.8% | $887K | — |
| Selling, general and administrative | $35.2M-40.1% | $58.8M+24.3% | $47.3M |
| Research and development | $8.9M-25.2% | $11.8M-41.7% | $20.3M |
| Loss on disposal of equipment | $246K+196.4% | $83K-96.7% | $2.5M |
| Total operating expenses | $47.8M-35.0% | $73.5M+3.7% | $70.9M |
| Loss from operations | -$12.2M+81.5% | -$65.9M-0.2% | -$65.8M |
| Interest income | $929K-34.4% | $1.4M-48.3% | $2.7M |
| Interest expense | -$7.7M+17.7% | -$9.4M-137.6% | -$4.0M |
| Change in fair value of derivative liability | $2.6M+200.0% | -$2.6M | $0 |
| Loss on extinguishment of debt | -$1.5M | $0 | — |
| Other expense | -$3K+82.4% | -$17K-21.4% | -$14K |
| Total other expense, net | -$5.7M+46.5% | -$10.7M-762.5% | -$1.2M |
| Net loss | -$17.9M+76.6% | -$76.6M-14.3% | -$67.0M |
| Net loss per share, basic (in shares) | -$2K+88.6% | -$15K-898.6% | -$1K |
| Net loss per share, diluted (in shares) | -$2K+88.6% | -$15K-898.6% | -$1K |
| Weighted-average common shares outstanding, basic (in dollars per share) | $10.65B+105.6% | $5.18B-88.6% | $45.34B |
| Weighted-average common shares outstanding, diluted (in dollars per share) | $10.65B+105.6% | $5.18B-88.6% | $45.34B |
| Product revenue, net | |||
| License and collaboration revenue | |||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Transcript: Verrica Pharmaceuticals Q1 2026 Earnings Conference Call
Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...